Subfoveal choroidal thickness response to anti-VEGF treatment in wet AMD

Session Details

Session Title: Free Paper Session 4: AMD II

Session Date/Time: Thursday 07/09/2017 | 11:00-12:30

Paper Time: 12:06

Venue: Room 111

First Author: : A.Abreu PORTUGAL

Co Author(s): :    L. Malheiro   V. Lages   M. Gomes   M. Macedo   M. Furtado   M. Lume              

Abstract Details

Purpose:

To evaluate the changes in subfoveal choroidal thickness (CT) during the first year of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) agents as treatment for neovascular age-related macular degeneration (AMD) patients.

Setting:

Department of Ophthalmology of a tertiary referral centre in Oporto, Portugal - Centro Hospitalar e Universitário do Porto

Methods:

Retrospective chart review of medical records of 24 treatment-naïve, consecutive patients (25 eyes) who were diagnosed with neovascular AMD and received intravitreal anti-VEGF treatment in pro re nata or treat and extend regimen. Subfoveal CT was measured with images obtained using spectral domain optical coherence tomography (Spectralis - Helderberg) at baseline and at 3, 6 and 12 months. Central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were analyzed at baseline and during follow-up visits.

Results:

Twenty-five eyes (24 patients) were included. Fifteen eyes were treated exclusively with bevacizumab, 5 eyes exclusively with aflibercept and in 5 eyes, who did not respond to 3 to 6 months bevacizumab treatment, therapy was switched to aflibercept. BCVA improved from 0.3±0.2 at baseline to 0.34±0.2 at 12 months after treatment (p<0.05). Subfoveal CT decreased from 207.8±56.6 μm at baseline to 184.3±59.6 μm at 3 months (p 0.024), 178.6±60.1 μm at 6 months (p 0.017) and 182±58.2 μm at 12 months (p 0.029). CFT improved from 391.8±217.9 μm at baseline to 242.1±70.2 μm at the end of follow-up (p 0.01).

Conclusions:

Both intravitreal bevacizumab and aflibercept significantly decreased subfoveal CT. The decreasing effect of anti-VEGF agents on choroidal thickness was highest in the first three months. Switching therapy to aflibercept did not influence subfoveal CT.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy